News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InNexus Biotechnology Inc. (IXS) To Host A Webcast Teleconference Detailing Recent News on Royalty Pharma AG Agreement & Preliminary Results of DXL625 Animal Study



2/8/2008 3:07:36 PM

BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB: IXSBF)(TSX VENTURE: IXS), (http://www.ixsbio.com) Chairman and CEO, Jeff Morhet will host a webcast teleconference on Monday, February 11, 2008 at 11:00 AM ET to discuss recent announcement with Royalty Pharma and preliminary results of an in vivo animal study exhibiting DXL625 (CD20)’s efficacy in reducing the growth rate of lymphoma cancer tumors.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES